sildenafil-citrate has been researched along with Hyperprolactinemia* in 3 studies
1 review(s) available for sildenafil-citrate and Hyperprolactinemia
Article | Year |
---|---|
Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review.
There is limited evidence for the management of sexual dysfunction and/or hyperprolactinemia resulting from use of antipsychotics in patients with schizophrenia and spectrum. The aim of this study was to review and describe the strategies for the treatment of antipsychotic-induced sexual dysfunctions and/or hyperprolactinemia. The research was carried out through Medline/PubMed, Cochrane, Lilacs, Embase, and PsycINFO, and it included open labels or randomized clinical trials. The authors found 31 studies: 25 open-label noncontrolled studies and 6 randomized controlled clinical trials. The randomized, double-blind controlled studies that were conducted with adjunctive treatment that showed improvement of sexual dysfunction and/or decrease of prolactin levels were sildenafil and aripiprazole. The medication selegiline and cyproheptadine did not improve sexual function. The switch to quetiapine was demonstrated in 2 randomized controlled studies: 1 showed improvement in the primary outcome and the other did not. This reviewed data have suggested that further well-designed randomized controlled trials are needed to provide evidence for the effects of different strategies to manage sexual dysfunction and/or hyperprolactinaemia resulting from antipsychotics. These trials are necessary in order to have a better compliance and reduce the distress among patients with schizophrenia. Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Substitution; Drug Therapy, Combination; Erectile Dysfunction; Female; Humans; Hyperprolactinemia; Male; Piperazines; Psychotic Disorders; Purines; Quinolones; Schizophrenia; Schizophrenic Psychology; Sexual Dysfunction, Physiological; Sildenafil Citrate; Sulfones; Vasodilator Agents | 2012 |
2 other study(ies) available for sildenafil-citrate and Hyperprolactinemia
Article | Year |
---|---|
Severe erectile dysfunction is a marker for hyperprolactinemia.
The need for routine prolactin (PRL) measurement in the initial evaluation of erectile dysfunction (ED) has been questioned because of the low rate of hyperprolactinemia (HP) in these men and the costs involved. In addition, it is widely thought that sexual desire problems are a good clinical marker for HP and/or low testosterone in men with ED. Within a 15-month period, 844 consecutive PRL and sexual hormone determinations were conducted in men at the Kingston General Hospital. Of these patients, 138 were comprehensively evaluated at the first visit for ED and completed the International Index of Erectile Function (IIEF). In the 138 patients, 2.2% had severe hyperprolactinemia (>35 ng/ml), within the range of 1-5% previously reported. No correlation between initial prolactin value and the sexual desire domain or the erectile function domain (EFD) of the IIEF was found for this population. However, all cases of severe HP were found to occur in men who scored less than 10 in the EFD of the IIEF. Low libido is widely accepted as a marker of HP. In this study, HP was found in patients not reporting major problems with a desire disorder. Clinically significant HP may be reliably found with routine biochemical evaluation and in this series was not detected in patients with EFD scores above 10. A routine PRL measurement is inexpensive and early detection of a serious and treatable disease may afford greater therapeutic success. Topics: Adult; Aged; Aged, 80 and over; Erectile Dysfunction; Humans; Hyperprolactinemia; Libido; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prolactin; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfones | 2001 |
Is management of impotence with sildenafil changing clinical practice?
Topics: Adult; Diagnosis, Differential; Diagnostic Errors; Erectile Dysfunction; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Practice Patterns, Physicians'; Purines; Sildenafil Citrate; Sulfones | 1999 |